



OPEN ACCESS

EDITED AND REVIEWED BY
Luisa Lanfrancione,
European Institute of Oncology (IEO), Italy

*CORRESPONDENCE

Lei Shang,
✉ shangleiia@163.com
Tao Jiang,
✉ jiangtaochest@163.com

†These authors have contributed equally to this work and share first authorship

RECEIVED 07 February 2025
ACCEPTED 28 April 2025
PUBLISHED 13 May 2025

CITATION

Lu Q, Ni Y, Wang W, Wang L, Jiang T and Shang L (2025) Corrigendum: Dynamin 3 inhibits the proliferation of non-small-cell lung cancer cells by suppressing c-MET–GBR2–STAT3 complex formation. *Front. Cell Dev. Biol.* 13:1566930. doi: 10.3389/fcell.2025.1566930

COPYRIGHT

© 2025 Lu, Ni, Wang, Wang, Jiang and Shang. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Dynamin 3 inhibits the proliferation of non-small-cell lung cancer cells by suppressing c-MET–GBR2–STAT3 complex formation

Qiang Lu^{1†}, Yunfeng Ni^{1†}, Wuping Wang¹, Lei Wang¹, Tao Jiang^{1*} and Lei Shang^{2*}

¹Department of Thoracic Surgery, Tangdu Hospital, The Air Force Military Medical University, Xi'an, China, ²The Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Health Statistics, School of Public Health, The Air Force Military Medical University, Xi'an, China

KEYWORDS

dynamin 3, lung cancer, non-small-cell lung cancer, growth factor receptor-bound protein 2, antitumor effect

A Corrigendum on

Dynamin 3 inhibits the proliferation of non-small-cell lung cancer cells by suppressing c-MET–GBR2–STAT3 complex formation

by Lu Q, Ni Y, Wang W, Wang L, Jiang T and Shang L (2021). *Front. Cell Dev. Biol.* 9:641403. doi: 10.3389/fcell.2021.641403

In the published article, there was an error in [Figure 6B](#) as published. The wrong bar chart for SNAIL mRNA was erroneously inserted for [Figure 6B](#). The corrected [Figure 6](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 6

The c-MET inhibitor has tumor suppressive effects on DNM3-depleted lung cancer cells and tumors. (A–D) H1299 cells with or without stable DNM3 knockdown were treated with 10 μ M crizotinib (CZT) for 24 h. (A) Western blot assay of the expression of the indicated proteins. (B) RT-qPCR assay of the mRNA levels of CCND1 and SNAIL. (C) BrdU assay of cell proliferation. (D) Transwell assay of the migration of the cells. (E) Nude mice xenografted with H1299 cells with or without stable DNM3 knockdown were treated with CZT (35 mg/kg per day for 12 days) by oral gavage (n = 5 for each group). The tumor growth was monitored. (F) Nude mice (n = 5 for each group) injected via the tail vein with H1299 cells with or without stable DNM3 knockdown were treated with CZT (35 mg/kg per day for 12 days) by oral gavage (n = 5 for each group). The number of metastatic tumor nodules in the lung was counted. Experiments for (A–D) were repeated 3 times. *p < 0.05; **p < 0.01; ***p < 0.001.